Overview

Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability?

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Warfarin is highly effective for the prevention of both first and recurrent thrombotic events, however even minor excursions outside the reference INR range of 2.0 to 3.0 are associated with bleeding or thrombotic complications. The importance of maintaining the INR within the desired interval has led to the concept of "time in therapeutic range (TTR)" - the total proportion of time that the INR is between 2.0 and 3.0. The investigators propose a multicentre, double blind, randomized trial which will determine if 0.150 mg of oral vitamin K increases time in the therapeutic range for patients receiving warfarin.
Phase:
Phase 3
Details
Lead Sponsor:
St. Joseph's Healthcare Hamilton
Collaborators:
McMaster University
University of Western Ontario, Canada
Treatments:
Vitamin K
Vitamin K 1
Vitamins
Warfarin